Akari Therapeutics Announces 1-for-40 Reverse ADS Split to Maintain Nasdaq Listing

summarizeSummary

Akari Therapeutics Plc announced a 1-for-40 reverse split of its American Depositary Shares (ADSs), effective March 31, 2026, to regain compliance with Nasdaq's minimum bid price requirement.

check_boxKey Events

• ADS Ratio Change Announced

  Akari Therapeutics will change its ADS ratio from 1 ADS representing 2,000 ordinary shares to 1 ADS representing 80,000 ordinary shares.

• 1-for-40 Reverse ADS Split

  This ratio change effectively results in a 1-for-40 reverse split of the company's issued and outstanding American Depositary Shares.

• Nasdaq Compliance Goal

  The primary purpose of the reverse split is to enable the company to maintain compliance with the Nasdaq minimum bid price requirement for continued listing.

• No Assurance of Compliance

  The company explicitly stated it can give no assurance that the ratio change will result in satisfying and maintaining the Nasdaq minimum bid price requirement.

auto_awesomeAnalysis

This reverse ADS split is a critical measure for Akari Therapeutics to avoid delisting from Nasdaq, signaling significant challenges with its stock price, which is currently trading near its 52-week low. While intended to boost the per-share price for compliance, the company explicitly stated there is no assurance this action will be sufficient to maintain listing. Investors should be aware that reverse splits often do not lead to sustained price appreciation and can sometimes be followed by further price declines or dilutive financing. This action contrasts with recent insider investments, suggesting a complex financial situation.